Drug Trial Radar · NCT00492986
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,150
Actual
Start
Oct 2005
Primary completion
Nov 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 27, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose of the study: The purpose of this study is to make sorafenib available for patients with advanced Renal Cell Carcinoma, who have failed prior systemic therapy for advanced disease (i.e. requiring second line treatment), and who do not have access to or are not eligible for other clinical trials with sorafenib and who may benefit from treatment with sorafenib. Patients will be treated orally with 400 mg bid sorafenib on a continuous basis and as a single agent. Patients may continue treatment until Disease Progression, intolerable toxicity, the patients chooses to withdraw consent or the patient is unlikely to benefit any further from treatment. Overall, participation in the study will help determine the following: * Find out if patients receiving Sorafenib will live longer * Find out if Sorafenib helps to slow the worsening of kidney cancer * Find out if Sorafenib has an effect on the tumours
Conditions
- Carcinoma, Renal Cell
Interventions
Nexavar (Sorafenib, BAY43-9006)Drug
Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety ParametersTime frame: Continously
Locations
33 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Bruxelles - Brussel, Belgium
Site not named
Leuven, Belgium
Site not named
Århus C, Denmark
Site not named
Bordeaux, France
Site not named
Lyon, France
Site not named
Villejuif, France
Site not named
München, Bavaria, Germany
Site not named
Hamburg, Free and Hanseatic City of Hamburg, Germany
Site not named
Darmstadt, Hesse, Germany
Site not named
Düsseldorf, North Rhine-Westphalia, Germany
Site not named
Koblenz, Rhineland-Palatinate, Germany
Site not named
Mainz, Rhineland-Palatinate, Germany
Site not named
Homburg, Saarland, Germany
Site not named
Dresden, Saxony, Germany
Site not named
Lübeck, Schleswig-Holstein, Germany
Site not named
Berlin, State of Berlin, Germany
Site not named
Milan, Italy
Site not named
Modena, Italy
Site not named
Pavia, Italy
Site not named
Perugia, Italy
Site not named
Reggio Emilia, Italy
Site not named
Amsterdam, Netherlands
Site not named
Warsaw, Poland
Site not named
Barcelona, Barcelona, Spain
Site not named
Madrid, Madrid, Spain
Site not named
Oviedo, Principality of Asturias, Spain
Site not named
Gothenburg, Sweden
Site not named
Stockholm, Sweden
Site not named
Basel, Canton of Basel-City, Switzerland
Site not named
Geneva, Canton of Geneva, Switzerland
Site not named
London, London, United Kingdom
Site not named
Glasgow, Stratchclyde, United Kingdom
Site not named
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.